There are 28 papers on Castelli risk index I in aging research: 12 trials and 16 observational studies in people.
28 papers study it4 more mention it6 findings
4 new papers in 30 daysSee all 32 papers on Castelli risk index I
“After full adjustment, higher CRI-I levels were associated with progressively lower odds of sarcopenia.”
- Human trial12
- Humans16
Interventions
3Resveratrol
no changein humans1
1 study
Resveratrol
no changein humans1
Resveratrol showed no clear effect on Castelli risk index I in humans (− 0.25 ± 0.9 vs. − 0.09 ± 0.5).
“After adjusting for confounding variables (medications, diabetes duration, energy intake and physical activity), no significant difference was also revealed in mean changes of LAP (− 2.46 ± 23.3 vs. 1.43 ± 14.3; P = 0.43), VAI (− 0.25 ± 1.1 vs. − 0.02 ± 0.6; P = 0.47), CRI-I (− 0.25 ± 0.9 vs. − 0.09 ± 0.5; P = 0.79”
Human trial8 weeksn = 76
BMC cardiovascular disorders
Resveratrol showed no clear effect on Castelli risk index I in humans (overweight type 2 diabetes) (mean change: - 0.25 ± 0.9 vs. - 0.09 ± 0.5; P = 0.79).
“no significant difference was found between the intervention group and the control group in LAP”
Human trialoverweight type 2 diabetes1000 mg/day8 weeksn = 71
BMC cardiovascular disorders
Exercise
downin humans1
1 study
Exercise
downin humans1
Exercise decreases Castelli risk index I in humans (sedentary middle-aged women) (-11.7%, p < 0.001).
“Castelli risk index I (−11.7%, p < 0.001), and Castelli risk index II (−14.6%, p < 0.001)”
Human trialsedentary middle-aged women20-weekfemalesn = 15
World Journal of Public Health
Taurine
downin humans1
1 study
Taurine
downin humans1
Taurine decreases Castelli risk index I in humans (before and after incremental exercise in heart failure patients).
“Our results also show that atherogenic indices [Castelli's Risk Index-I (CRI-I), Castelli's Risk Index-II (CRI-II) and Atherogenic Coefficient (AC)] decreased in the taurine group”
Human trialbefore and after incremental exercise in heart failure patients500 mg three times a day2 weeks
Therapeutic advances in cardiovascular disease
Associations
2Cardiovascular and cerebrovascular disease mortality
upin humans1HR 1.35
1 study
Cardiovascular and cerebrovascular disease mortality
upin humans1HR 1.35
Castelli risk index I predicts cardiovascular and cerebrovascular disease mortality in humans (type 2 diabetes mellitus) (HR: 1.35, 95% CI: 1.02 - 1.78, p = 0.038).
“The -CRI-I predicted CCVD deaths in elderly T2DM patients (HR: 1.35, 95% CI: 1.02 - 1.78, p = 0.038) after fully adjusting for age, gender, smoking, drinking”
Humanstype 2 diabetes mellitus7.62 yearsn = 888
Biomarkers in medicine
Sarcopenia
downin humans1
1 study
Sarcopenia
downin humans1
Castelli risk index I is associated with sarcopenia in humans after full adjustment.
“After full adjustment, higher CRI-I levels were associated with progressively lower odds of sarcopenia.”
Humansafter full adjustment
Lipids in health and disease